Is Savaysa already dead?

The weekly Rx totals, especially NRx, are pathetic. Below 1,000 a week and have already plateaued. Is there any hope? That giant sucking sound is the massive reorg coming to DSI at the end of the year.

 

It's dead because u haven't sold anything relevant in 10 years. Take the skirt off and actually challenge your customers rather than complaining. The days of benicar are gone so read your modules and figure out a way to actually do some work. Seriously the people who bitch and moan need to go so we can get some hungry reps who want to work in this company. The fact that u would post such a comment proves that u suck and need to find another gig.

 

Typical BS. Sell harder crap. Did you ever think this drug sucks? How about that hero?

 

Think about it..dsi announced a scary layoff two weeks following launch. Does anyone really think Svs is going to rock volume during this period?
Simply put, if there is doubt(ie loss of job or Job instability) humans by nature lose focus. In dsi's case. Most PC reps were not sure on jobs, dms have and had no clue so passion was lost during sales calls.

 

It's kind of hard to sell a drug with a massive black box warning about normal patients and almost zero MM access. Seriously, why would a doctor bother with Savaysa and the potential headaches when X and E are so easy to write? And both have better indications. Sell harder? Yeah, that will work.

 

If your on Cafe Pharma, we all suck.

 

That's a pretty fair assumption

 

Typical DSM response.

 

Then leave. Why are you in sales? Everything was handed to you in life? Now you run into a little resistance and you don't know how to handle it.

 

Home office employee here. A lot of talk about major lay-off end of year. Possibly getting ready for acquisition from another company. This place is awful.

 

You both are right. This is a pointless discussion

 

Being acquired isn't necessarily a bad thing. Sometimes it's a very good thing.

 

If we had stock options it would be

 

Home office folks, the unlucky ones that didn't get packages last month, are begging and hoping for an acquisition. DS Global is hurting as well. Their revenue will drop by 30-40%. Better that DSI's (i.e., US) drop in revenue of 85%, but still awful.

The word is that Astellas may put an end to our misery. Most reps and HO people will be cut and others would have to move to Chicago, but at least everyone will get a nice package. Fingers crossed!

 

That's the truth. Benicar sells itself as long as it has MM coverage. Welchol was truly a relationship sell where the good reps could prove their worth. But bad drugs like Savaysa can't be sold even if Jesus was repping it. It's a bad drug with a bad label.

 

This is the most accurate thing I've ever read on here.

 

Read the fourth paragraph

http://www.fiercepharma.com/story/daiichi-sankyo-gets-ema-recommendation-clot-buster/2015-04-24

 

To pull out the quote. Ouch, and those measly sales are worldwide, so only projecting about half of that in the US:

Estimates are the anticoagulant could bring in $220 million in sales for fiscal 2019, but that is roughly one-tenth of the revenue generated by cardio blockbuster Benicar. The drug's $2.6 billion haul last fiscal year accounted for 27% of Daiichi Sankyo's revenues. The company is making cost-cutting moves as well, and last month said it would whack 16% of its U.S. staff, with more cuts possibly coming. Analyst musings have been that Daiichi will not see growth for 5 years.

 

Movantik is already D.O.A., even before we've had the chance to sell it. Launch trajectories make or break drugs these days.

 

Based on what information?